Cryogenic logistics company Cryoport, Inc. has signed a deal with ProMab Biotechnologies to transport its immune-therapeutic alternatives for cancer treatment throughout China.
Cryoport’s depot in Singapore will primarily support the transport of ProMab’s samples in this case, as ProMab builds-outs its new chimeric-antigen receptors T-cells (CAR-T) engineering segment of its business at its manufacturing site in China.
The Cryoport Solution, comprised of the CryoportalTM logistics management platform and SmartPak IITM condition monitoring system, facilitates the storage and monitoring of static samples and manages a fleet of dewars to transport temperature-sensitive materials.
... to continue reading you must be subscribed
